Coming soon in pharmacological bodybuilding: DS20060511
Researchers at the Japanese pharmaceutical company Daiichi Sankyo have discovered a potential diabetes drug that can replace insulin, or at least enhance the action of insulin. When we read Daiichi's publication on DS20060511 in Communications Biology, we were almost certain. Sooner or later, this substance will show up in pharmacological bodybuilding.[FONT="]
[/FONT]
[FONT="]
[/FONT]
Activates GLUT4
When muscles are active, they absorb more glucose. In muscle cells, physical activity stimulates glucose transporter GLUT4 to absorp glucose from the bloodstream into the cell. When Daiichi screened more than 100,000 substances for their property to trigger GLUT4, the company stumbled upon DS20060511.A problem with many diabetes drugs is that while they lower glucose levels and allow the organs to absorb more glucose, they also increase fat tissues. The Japanese hope that a drug that works via GLUT4 would not have this disadvantage.
And good heavens! DS20060511 allows muscle cells to absorb more glucose, but has no effect on the uptake of glucose by fat cells.
[FONT="]
[/FONT]
[FONT="]
[/FONT]
Is orally active
The figures you see below are based on experiments with mice that were given DS20060511 orally, plus a dose of glucose. Compared to a control group, the drug lowers glucose and insulin levels after taking it for a few hours.
If you translate the doses to adult humans, they are approximately between 8-240 milligrams.
[FONT="]
[/FONT]
[FONT="]
[/FONT]
[FONT="]
[/FONT]
Does not improve endurance performance
Administration of DS20060511 failed to increase the mice's endurance capacity. During exercise, the test animals burned more glucose, but less fatty acids.
Nota bene, the researchers did use a high dose. The experiment might have had a different result at a lower dose.
[FONT="]
[/FONT]
[FONT="]
[/FONT]
[FONT="]
[/FONT]
Pumps muscles full of glucose
In an experiment in which the researchers gave their lab animals a traceable glucose analogue [2DG] plus DS20060511, the new drug stimulated the uptake of the glucose analogue by the muscles. This suggests that DS20060511 may well be a body recompositioning drug.
At least if the substance is not toxic. The researchers write between the lines that they assume that this is not the case, but we have not been able to find any toxicological research into DS20060511.
Source:
Commun Biol. 2021 Aug 20;4(1):994.
|
[/FONT]
[FONT="]
[/FONT]
Activates GLUT4
And good heavens! DS20060511 allows muscle cells to absorb more glucose, but has no effect on the uptake of glucose by fat cells.
[FONT="]
[/FONT]
[FONT="]
[/FONT]
Is orally active
The figures you see below are based on experiments with mice that were given DS20060511 orally, plus a dose of glucose. Compared to a control group, the drug lowers glucose and insulin levels after taking it for a few hours.
If you translate the doses to adult humans, they are approximately between 8-240 milligrams.
[FONT="]
[/FONT]
[FONT="]
[/FONT]
[FONT="]
[/FONT]
Does not improve endurance performance
Administration of DS20060511 failed to increase the mice's endurance capacity. During exercise, the test animals burned more glucose, but less fatty acids.
Nota bene, the researchers did use a high dose. The experiment might have had a different result at a lower dose.
[FONT="]
[/FONT]
[FONT="]
[/FONT]
[FONT="]
[/FONT]
Pumps muscles full of glucose
In an experiment in which the researchers gave their lab animals a traceable glucose analogue [2DG] plus DS20060511, the new drug stimulated the uptake of the glucose analogue by the muscles. This suggests that DS20060511 may well be a body recompositioning drug.
At least if the substance is not toxic. The researchers write between the lines that they assume that this is not the case, but we have not been able to find any toxicological research into DS20060511.
Source:
Commun Biol. 2021 Aug 20;4(1):994.
